The Global Asthma & Copd Therapies Market Was Valued At $32.9bn In 2016
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
LONDON, Nov. 14, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5196137
The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.
The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.
Report Scope
-Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:- Global Asthma Therapies Market forecasts- Global COPD Therapies Market forecasts
-Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
- Bronchodilators monotherapy
- Anti-inflammatory drugs
- Combination drugs
• Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:- Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex- Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,- Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris
• Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
- Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
- Anti-leukotrienes: Singulair
- Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
• Revenue forecast for the Combination drugs market and the leading drugs:- Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo
• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
- The US
- Japan
- EU5: Germany, France, UK, Italy, Spain
- BRIC: Brazil, Russia, India, China
- Mexico
- Other Countries
• This report discusses the leading companies in the global asthma & COPD therapies market:- GSK- Boehringer Ingelheim- AstraZeneca- Novartis- Merck- Roche- Teva
• This report discusses drugs currently in clinical development for treating asthma and COPD.
• This report discusses the SWOT analysis as well as porter's five forces analysis of the global asthma & COPD therapies market.
Download the full report: https://www.reportbuyer.com/product/5196137
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article